Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

  • STATUS
    Recruiting
  • End date
    Jul 13, 2024
  • participants needed
    272
  • sponsor
    Supernus Pharmaceuticals, Inc.
Updated on 13 April 2022
stroke
traumatic brain injury
hemiplegia
myobloc

Summary

Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of lower limb spasticity, in adults followed by an open-label extension safety trial.

Description

Phase 2, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial will compare the efficacy and safety of two doses of MYOBLOC versus volume-matched placebo in the treatment of lower limb spasticity in adults. An interim analysis will evaluate all available safety and efficacy data from the Phase 2 double-blind trial in order to recommend which dose will be evaluated in subsequent Phase 3 trial. The Phase 3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial will compare the efficacy and safety of MYOBLOC versus placebo in the treatment of lower limb spasticity in adults. Subjects who complete either the Phase 2 or Phase 3 trial will continue into an open-label extension where each will receive 5 separate MYOBLOC treatments (~13 week apart) for lower limb spasticity.

Details
Condition Spasticity
Treatment Placebo, rimabotulinumtoxinB, Phase 2; Low Dose MYOBLOC, Phase 2; High Dose MYOBLOC, Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
Clinical Study IdentifierNCT04099667
SponsorSupernus Pharmaceuticals, Inc.
Last Modified on13 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Able to understand the potential risks and benefits, the study requirements, and provide written informed consent before enrollment into the study; or if unable, the subject's Legally Authorized Representative (LAR) may provide written informed consent
Male or female ≥18 to maximum of 80 years of age, inclusive
Lower limb spasticity due to stroke, traumatic brain injury, or spinal cord injury that occurred ≥6 months prior to randomization. Eligible subjects may have lower limb monoplegia or hemiplegia. Subjects with cerebral palsy are eligible for study enrollment
Ambulatory (with or without the use of a walking assistive device)
Modified Ashworth Scale (MAS) score ≥2 in the ankle plantar flexors of the affected lower limb at screening and at baseline
In the Investigator's opinion, the subject will be available and able to comply with the study requirements for at least 1 year, based on the subject's overall health and disease prognosis
In the Investigator's opinion, the subject will be willing and able to comply with all requirements of the protocol, including completion of study questionnaires. A caregiver may be designated to assist with the physical completion of questionnaires/scales

Exclusion Criteria

Quadriplegia/tetraplegia, lower limb diplegia or triplegia
Neuromuscular disorders including, but not limited to, amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), multiple sclerosis (MS), myasthenia gravis, or muscular dystrophy
Known hypersensitivity to botulinum toxins type A or B or to any MYOBLOC solution components
Uncontrolled epilepsy or any type of seizure disorder with a seizure(s) within the previous year
History of major joint contracture(s), in which, based on the Investigator's assessment, the contracture(s) significantly contribute(s) to joint immobility in the affected lower limb
Unresolved fracture(s) in the affected lower limb
Obstructive pulmonary disease with forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) <70%
Severe atrophy in the affected lower limb
Concomitant use or exposure within 5 half-lives of randomization of the following: aminoglycoside antibiotics, curare-like agents, or other agents that may interfere with neuromuscular function
Treatment with a neurolytic agent (e.g., phenol, alcohol blocks) to the affected lower limb within 1 year before randomization
Presence of a spinal stimulator or intrathecal baclofen pump that has not been turned off within 30 days before screening
Changes to treatment regimen or any new treatment with oral antispasmodics and/or muscle relaxants within 30 days before randomization
Initiation of physical and/or occupational therapy <30 days before randomization. Subjects receiving physical and/or occupational therapy ≥30 days before randomization must be willing to maintain their therapy regimen through Week 4 of the DBP
Application of an ankle-foot orthosis (AFO) <30 days before randomization. Subjects regularly using an AFO ≥30 days before randomization must be willing to maintain use of the AFO through Week 4 of the Double-Blind Period
Prior botulinum toxin type A (BoNT/A) or B (BoNT/B) treatment in the affected lower limb within 24 weeks before screening. Prior BoNT/A or BoNT/B treatment in areas other than the affected lower limb is not exclusionary but must have occurred at least 12 weeks before screening. Prior toxin exposure must have been well tolerated and without any significant long-term side effects in the case of repeated prior exposure
Subjects should not receive nor have any plans to receive any botulinum toxin treatment, other than the study drug (MYOBLOC), from the point informed consent is obtained until participation in the study is complete
Severe dysphagia (i.e., inability to swallow liquids, solids or both without choking or medical intervention), or dysphagia with a history of aspiration pneumonia, within 6 months before screening
Prior surgery to treat spasticity in the affected lower limb (i.e., tendon lengthening or tendon transfer)
Any anticipated or scheduled surgery during the study period, with the exception of dermatological procedures performed under local anesthesia for the purposes of removing precancerous and cancerous lesions
Major surgery within 3 months before screening
Pregnancy or breastfeeding
Females of childbearing potential must agree to practice a medically acceptable method of contraception (e.g., intrauterine device, hormonal contraception started at least one full cycle before study enrollment or barrier method in conjunction with spermicide) for the duration of the study (including 2 months after study completion). For the purposes of this study, all females are considered to be of childbearing potential unless they are confirmed by the Investigator to be post-menopausal (at least 1 year since last menses and laboratory test confirmation), biologically sterile, or surgically sterile (e.g., hysterectomy with bilateral oophorectomy, tubal ligation)
History of drug or alcohol abuse within 6 months before screening
Slow vital capacity (SVC) <60% of predicted
Chronic or current use of inhaled corticosteroids
Ventilator dependence (i.e., 24-hour ventilator dependence when intubated, or due to a failure to wean the subject from the ventilator while hospitalized in the intensive care unit or respiratory care center). Subjects who use oxygen on an as-needed basis or during sleeping hours only via a nasal cannula are eligible for the study
Infection at the planned sites of injection
Treatment with an investigational drug, device, or biological agent within 30 days before screening or while participating in this study
Malignancy diagnosed 3 months before screening
Has one or more screening clinical laboratory test values outside the reference range that, in the opinion of the Investigator, are clinically significant, or any of the following
Serum creatinine >1.5 times the upper limit of normal (ULN)
Serum total bilirubin > 1.5 times ULN
Serum alanine aminotransferase or aspartate aminotransferase >2 times ULN
Has any of the following cardiology findings at screening
Abnormal ECG that is, in the Investigator's opinion/evaluation, clinically significant
PR interval >220 ms
QRS interval >130 ms
QTcF interval >450 ms (for men), or >470 ms (for women) (QT corrected using Fridericia's method)
Second-or third-degree atrioventricular block
Any rhythm, other than sinus rhythm, that is interpreted or assessed by the Investigator to be clinically significant
Any other medical illness, condition, or clinical finding that, in the opinion of the
Investigator and/or the Sponsor, would put the subject at undue risk
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note